EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predicting the risk of ibrutinib in combination with R-ICE in patients with relapsed or refractory DLBCL using explainable machine learning algorithms

Ni Zhu, Rong-Bin Shen, Jun-Fa Chen, Jian-You Gu, Si-Chun Xiang, Yu Zhang, Li-Li Qian, Qing Guo, Sha-Na Chen, Jian-Ping Shen, Jun Yan, Jing-Jing Xiang

Clinical and Experimental Medicine · 2025

DOI: 10.1007/s10238-025-01709-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Ni Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Ha…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Machine Learning, Adenine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation, This work was supported by Special project for the modernization of traditional Chinese medicine in Zhejiang province, Zhejiang Traditional Medicine and Technology Program for Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses significant therapeutic challenges due to heterogeneous patient outcomes. This study aimed to evaluate the efficacy of the ibrutinib plus R-ICE regimen and to leverage explainable machine learning models (ML) for predicting treatment risks and outcomes. Retrospective data from 28 patients treated between March 2019 and July 2022 were analyzed. Machine learning models, including CoxBoost + StepCox, were developed and validated using bootstrap methods. Synthetic minority over-sampling combined with propensity score matching (SMOTE-PSM) addressed class imbalances. Prognostic performance was compared against the Cox proportional hazards model using decision curve and calibration analysis, as well as time-dependent ROC curves. The CoxBoost + StepCox model achieved an average C-index of 0.955 for overall survival (OS) and progression-free survival (PFS). Key prognostic indicators included elevated lactate dehydrogenase (LDH), initial treatment response, time to relapse > 12 months, and CD5 + expression. Calibration curves showed a C-index of 0.932 for OS and 0.972 for PFS in the training set. CD5 + was most predictive for OS and LDH for PFS. Machine learning models demonstrated high accuracy and clinical utility, indicating potential for data-driven treatment decisions in DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseMachine LearningAdenineAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedPiperidinesAdultPrognosisNeoplasm Recurrence, LocalRituximabAged, 80 and overCyclophosphamide

Stichwörter der Autor:innen

Diffuse large B-cell lymphomaICE chemotherapyIbrutinibMachine learningRituximab

Substanzen

ibrutinibAdeninePiperidinesRituximabCyclophosphamide

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, Zhejiang, China.
  • Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
  • Department of Hematology, Inner Mongolia International Mongolian Hospital, Hohhot, China.
  • Laboratory of Chemistry and Physics, Hangzhou Center for Disease Control and Prevention, Hangzhou (Hangzhou Health Supervision Institution), Hangzhou, 310021, Zhejiang, China. janjun@hzcdc.com.cn.
  • Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, Zhejiang, China. xiangjing071026@163.com.

Förderung

  • Zhejiang Provincial Natural Science Foundation
  • This work was supported by Special project for the modernization of traditional Chinese medicine in Zhejiang province
  • Zhejiang Traditional Medicine and Technology Program for Young Scholars

Zitieren

APA

Zhu, N., Shen, R. B., Chen, J. F., Gu, J. Y., Xiang, S. C., Zhang, Y., Qian, L. L., Guo, Q., Chen, S. N., Shen, J. P., Yan, J., & Xiang, J. J. (2025). Predicting the risk of ibrutinib in combination with R-ICE in patients with relapsed or refractory DLBCL using explainable machine learning algorithms. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01709-9

Vancouver

Zhu N, Shen RB, Chen JF, Gu JY, Xiang SC, Zhang Y, et al. Predicting the risk of ibrutinib in combination with R-ICE in patients with relapsed or refractory DLBCL using explainable machine learning algorithms. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-01709-9

BibTeX
@article{Zhu2025,
  author = {Zhu, Ni and Shen, Rong-Bin and Chen, Jun-Fa and Gu, Jian-You and Xiang, Si-Chun and Zhang, Yu and Qian, Li-Li and Guo, Qing and Chen, Sha-Na and Shen, Jian-Ping and Yan, Jun and Xiang, Jing-Jing},
  title = {Predicting the risk of ibrutinib in combination with R-ICE in patients with relapsed or refractory DLBCL using explainable machine learning algorithms},
  journal = {Clinical and Experimental Medicine},
  year = {2025},
  doi = {10.1007/s10238-025-01709-9}
}
Kostenlos starten →